AQST Stock Forecast & Price Target

Aquestive Therapeutics Inc. is positioned favorably within the no-needle epinephrine market, reflecting a growing demand for both oral and intranasal alternatives, which contributes to an optimistic outlook for the company. The recent announcement that the FDA will not require an Advisory Committee meeting for its New Drug Application (NDA) of Anaphylm has resulted in a significant stock surge of 43.77%, suggesting increased investor confidence regarding its approval prospects. Furthermore, the submitted data package appears robust enough to adequately address key regulatory considerations, potentially paving the way for successful market entry of its innovative product offerings.

Aquestive Therapeutics faces significant downside risks impacting its financial outlook, primarily related to the potential failure of AQST-109's development and expected declines in revenues from existing licensed commercial products. Additionally, the company may need to secure new capital to enhance its balance sheet, which can pose further financial strain. Despite a sizable market opportunity for alternative treatments such as a sublingual film for severe allergic reactions, these fundamental challenges could hinder the firm's performance and investor confidence.